Page last updated: 2024-10-21

4-aminopyridine and Facio-Scapulo-Humeral Dystrophy

4-aminopyridine has been researched along with Facio-Scapulo-Humeral Dystrophy in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Gene analysis for congenital myasthenic syndrome (CMS) revealed a new mutation in the DOK7 gene; the diagnosis of CMS was confirmed."1.40[Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy]. ( Mori-Yoshimura, M; Murata, M; Nakata, T; Nishikawa, A; Ohno, K; Okamoto, T; Oya, Y, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nishikawa, A1
Mori-Yoshimura, M1
Okamoto, T1
Oya, Y1
Nakata, T1
Ohno, K1
Murata, M1

Other Studies

1 other study available for 4-aminopyridine and Facio-Scapulo-Humeral Dystrophy

ArticleYear
[Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy].
    Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:7

    Topics: 4-Aminopyridine; Adult; Amifampridine; Diagnosis, Differential; Female; Humans; Menstrual Cycle; Mus

2014